---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-339223"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-08-07T12:00:15+00:00"
generated_at: "2026-08-07T12:05:20.972704+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gyre Q2 2026 net loss widens to $14.3M; FY revenue guidance affirmed at $100.5-111.0M

## Summary
- Q2 2026 revenue $29.1M, down 2% YoY; GAAP basic EPS $(0.12); net loss $14.3M vs $2.2M loss in Q2 2025.
- Non-GAAP adjusted net loss $12.2M vs $0.6M loss; R&D expense up 129% to $19.1M on F351 and milestone.
- Cullgen acquisition closed May 4, 2026, all-stock ~$300M; Dr. Ying Luo now CEO/President, new CSO/CFO named.
- NDA for F351 (CHB liver fibrosis) accepted by China's CDE in May 2026; full-year revenue guidance reaffirmed.
- Cash, deposits, and investments totaled $103.2M at June 30, 2026, down $12.9M from year-end 2025.

## SEC filing metadata
- accession: 0001193125-26-339223
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-08-07T12:00:15+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000119312526339223/0001193125-26-339223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000119312526339223/gyre-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-339223
- JSON: https://secwatch.observer/filing/0001193125-26-339223.json
- Plain text: https://secwatch.observer/filing/0001193125-26-339223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.